We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Trade like a pro: Leverage real-time discussions and market-moving ideas to outperform.
The current CARM market cap is 16.66M. The company's latest EPS is USD -2.0809 and P/E is -0.19.
| Quarter End | Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 |
|---|---|---|---|---|---|
| USD (US$) | USD (US$) | USD (US$) | USD (US$) | USD (US$) | |
| Total Revenue | 3.56M | 3.83M | 4.29M | 3.4M | 9.2M |
| Operating Income | -20.97M | -22.34M | -22.45M | -19.51M | -11.67M |
| Net Income | -19.88M | -21.4M | -20.96M | -18.98M | -11.16M |
| Year End 31 December 2023 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|
| USD (US$) | USD (US$) | USD (US$) | USD (US$) | USD (US$) | |
| Total Revenue | 0 | 22.42M | 83.38M | 92M | 14.92M |
| Operating Income | -108.49M | -21.08M | -8.55M | -25.91M | -88.73M |
| Net Income | -107.5M | -22.54M | -336k | -19.88M | -86.88M |
| Quarter End | Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 |
|---|---|---|---|---|---|
| USD (US$) | USD (US$) | USD (US$) | USD (US$) | USD (US$) | |
| Total Assets | 133.01M | 106.78M | 89.55M | 73.8M | 59.34M |
| Total Liabilities | 66.31M | 60.49M | 63.02M | 62.9M | 58.98M |
| Total Equity | 66.71M | 46.3M | 26.53M | 10.9M | 360k |
| Year End 31 December 2023 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|
| USD (US$) | USD (US$) | USD (US$) | USD (US$) | USD (US$) | |
| Total Assets | 114.37M | 122.82M | 240.75M | 189.17M | 89.55M |
| Total Liabilities | 141.07M | 132.05M | 69.04M | 30.98M | 63.02M |
| Total Equity | -26.7M | -9.23M | 171.71M | 158.19M | 26.53M |
| Quarter End | Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 |
|---|---|---|---|---|---|
| USD (US$) | USD (US$) | USD (US$) | USD (US$) | USD (US$) | |
| Operating | -44.08M | -65.08M | -81.18M | -22.43M | -38.55M |
| Investing | 32.16M | 61.97M | 72.41M | -17k | -123k |
| Financing | 64.11M | 62.08M | 62.18M | 1.35M | 1.43M |
| Year End 31 December 2023 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|
| USD (US$) | USD (US$) | USD (US$) | USD (US$) | USD (US$) | |
| Operating | -37.52M | -30.84M | -68.88M | 24.9M | -81.18M |
| Investing | -136k | -8k | -4k | -53.97M | 72.41M |
| Financing | 35.36M | 38.11M | 176.13M | 1,000 | 62.18M |
| Market Cap | 16.66M |
| Price to Earnings Ratio | -0.19 |
| Price to Sales Ratio | 1.12 |
| Price to Cash Ratio | 0.22 |
| Price to Book Ratio | 0.63 |
| Dividend Yield | - |
| Shares Outstanding | 41.75M |
| Average Volume (1 week) | 356.93k |
| Average Volume (1 Month) | 373.57k |
| 52 Week Change | -86.92% |
| 52 Week High | 3.16 |
| 52 Week Low | 0.3809 |
| Spread (Intraday) | 0 (0.03%) |
| Company Name | Carisma Therapeutics Inc |
| Address |
corporation trust center wilmington, delaware 19801 |
| Website | https://www.carismatx.com |
| Industry | pharmaceutical preparations (2834) |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
